Adel Malati
Internal Medicine · Okmulgee, OKNPI 1740286467
Payments from drug & device makers
Across 112 payments — averaging $14.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avanir Pharmaceuticals, Inc.$232
- Pfizer$146
- Sunovion Pharmaceuticals Inc.$138
- GSK$128
- Novo Nordisk$113
- Otsuka America Pharmaceutical, Inc.$98
- plus $763 from 15 others
What the payments were for
- Food & beverage$1,58898%
- Education$302%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avanir Pharmaceuticals, Inc. | 13 | $232 |
| Pfizer | 10 | $146 |
| Sunovion Pharmaceuticals Inc. | 17 | $138 |
| GSK | 9 | $128 |
| Novo Nordisk | 8 | $113 |
| Otsuka America Pharmaceutical, Inc. | 6 | $98 |
| Astellas Pharma US Inc | 6 | $98 |
| AbbVie(2 entities) | 6 | $97 |
| Lilly USA, LLC | 7 | $91 |
| Johnson & Johnson | 5 | $83 |
| Novartis | 5 | $74 |
| Acadia Pharmaceuticals Inc | 5 | $73 |
| Supernus Pharmaceuticals, Inc. | 4 | $64 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $49 |
| UCB, Inc. | 2 | $40 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Biogen | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$1,618 in reported general payments places this provider in the 75th percentile of 840 internal medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 35 | $10,927 |
| Memantine Hcl ErMemantine Hcl | 21 | $1,387 |
| Atorvastatin Calcium | 106 | $1,360 |
| Divalproex Sodium | 17 | $759 |
| Potassium Chloride | 29 | $738 |
| Furosemide | 41 | $573 |
| Tamsulosin Hcl | 34 | $547 |
| Metoprolol Tartrate | 32 | $471 |
| Gabapentin | 29 | $461 |
| Baclofen | 20 | $460 |
| Lamotrigine | 21 | $394 |
| Medroxyprogesterone Acetate | 21 | $391 |
| Levetiracetam | 18 | $359 |
| Levothyroxine Sodium | 34 | $296 |
| Lisinopril | 21 | $254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $146 | $10,92735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Okmulgee
- Al-Ola AbdallahTulsa$10.1M
- Melita TateTulsa$9.1M
- Sagila GeorgeOklahoma City$1.8M
- Ryan MorganOklahoma City$775K
- Renae MayerTulsa$766K
- George FreemanIdabel$742K
- Elise WiesnerNorman$584K
- Steve EgwuonwuLawton$464K
- Mousumi SomTulsa$391K
- Jesse RichardsTulsa$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.